Williams C J, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster D J, Rowland C, Tyrrell C
Department of Medical Oncology, Southampton General Hospital, United Kingdom.
Cancer Treat Rep. 1987 Dec;71(12):1197-201.
Trilostane, an inhibitor of the production of adrenal estrogens, was administered, together with dexamethasone, to 97 eligible postmenopausal women with advanced breast cancer. Seventy-four patients who had either received trilostane for a minimum of 10 weeks or whose disease had progressed while on trilostane before this period were assessed for tumour response. Eighteen patients (25%) had objective responses (two complete, 16 partial); a further 21 patients had stable disease. The response rate among all 97 patients, including those not treated for a minimum 10-week period, was 19%. Thirty-two of 97 patients reported adverse reactions which were attributed to trilostane and/or dexamethasone. Therapy was stopped for 15 patients, and the dose of trilostane was reduced for ten. Diarrhea was the commonest side effect, being reported in 16 patients, of whom nine stopped treatment. Trilostane, given with a corticosteroid, is an effective alternative hormonal agent acting by adrenal blockade for postmenopausal women with advanced breast cancer.
曲洛司坦是一种肾上腺雌激素生成抑制剂，与地塞米松一起给予了97名符合条件的绝经后晚期乳腺癌女性患者。对74名患者进行了肿瘤反应评估，这些患者要么接受曲洛司坦治疗至少10周，要么在此之前接受曲洛司坦治疗期间疾病进展。18名患者（25%）有客观反应（2例完全缓解，16例部分缓解）；另有21名患者疾病稳定。在所有97名患者中，包括未接受至少10周治疗的患者，缓解率为19%。97名患者中有32名报告了归因于曲洛司坦和/或地塞米松的不良反应。15名患者停止了治疗，10名患者减少了曲洛司坦剂量。腹泻是最常见的副作用，16名患者报告有腹泻，其中9名停止了治疗。曲洛司坦与皮质类固醇联合使用，是一种通过肾上腺阻断发挥作用的有效替代激素药物，用于绝经后晚期乳腺癌女性患者。
